BARCELONA, Spain — INBRAIN Neuroelectronics has appointed Scott Huennekens as chairman of its board of directors as the company moves toward pivotal trials and eventual commercialization of its graphene-based brain-computer interface therapeutics for neurological disorders.
Carolina Aguilar, CEO and co-founder of INBRAIN, said Huennekens’ background leading medical technology companies positions him to guide the company through its next stage of growth. “Scott brings an exceptional track record of scaling breakthrough medtech companies and guiding them through pivotal points of growth,” Aguilar said. “His experience in leading platform technologies, from imaging to surgical robotics and intelligent devices, will be invaluable as we advance our precision BCI therapeutics into later-stage clinical development. We are thrilled to welcome him as Chairman during a defining moment for the company.”
Huennekens has worked for more than two decades as an executive, founder and board member across multiple healthcare technology companies. He has led two start-ups that reached unicorn valuations and has been involved with more than 10 high-growth medtech companies with combined valuations exceeding $6 billion. According to the company, technologies developed under his leadership have reached more than 20 million patients.
Most recently, he served as president and chief executive officer of Verb Surgical, the surgical robotics joint venture formed by Google and Johnson & Johnson. Before that, he was the founding president and CEO of Volcano Corporation, which grew into a major provider of image-guided therapy systems before being acquired by Philips. He earlier held the roles of president and CEO at Digirad Corporation, which later went public on Nasdaq.
“INBRAIN is developing the most promising BCI therapeutic platform in the field,” Huennekens said. “Graphene offers a level of precision, biocompatibility, and signal quality that could enable safer, smarter, and true personalized real-time therapeutics. I’m excited to support Carolina and the team as we work to scale this technology and bring a new generation of neuroelectronic therapeutics to patients with neurological disease.”
Huennekens serves on the boards of NeuroPace, QuidelOrtho, Envista, Elucid and Kardion, and previously chaired the Medical Device Manufacturers Association. He is a graduate of the University of Southern California and holds an MBA from Harvard Business School.
